Clinical strategies for optimizing infusion center care through a pandemic

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

(2020) Wenhua Liang et al.   LANCET ONCOLOGY

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

(2020) Hannelore Denys et al.   BREAST CANCER RESEARCH AND TREATMENT

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

(2020) Mallika Lala et al.   EUROPEAN JOURNAL OF CANCER

A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience

(2019) Bart J. F. van den Bemt et al.   DRUG DELIVERY

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

(2019) Kari M. Morrissey et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting

(2019) Leila Jafari et al.   BLOOD

Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study

(2019) Ricardo García‐Muñoz et al.   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: A Retrospective Review

(2018) Daniel C. Kendzierski et al.   Clinical Breast Cancer

P713 Home-based vedolizumab infusions: A suitable alternative to routine hospital infusions

(2018) N Peek-Kuijt et al.   Journal of Crohns & Colitis

Outpatient High-dose Methotrexate for Osteosarcoma

(2018) Eleanor Hendershot et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Ninety-minute daratumumab infusion is safe in multiple myeloma

(2018) Hallie Barr et al.   LEUKEMIA

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

(2018) Axel Grothey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

(2018) Prudence A. Francis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

(2018) G V Long et al.   ANNALS OF ONCOLOGY

Safety profile and reduced observation time in outpatients using subcutaneous Herceptin.

(2018) Fabiano Hosken Pombo et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

(2018) Nicholas J Short et al.   Lancet Haematology

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

(2017) J. Gligorov et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

(2017) Pieternella Lugtenburg et al.   HAEMATOLOGICA

Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)

(2017) Charles L. Shapiro et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update

(2017) Catherine Van Poznak et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?

(2017) L Price et al.   European Journal of Hospital Pharmacy-Science and Practice

Ten-minute administration of bevacizumab

(2017) Sara García Gil et al.   European Journal of Hospital Pharmacy-Science and Practice

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

(2017) Pieternella Lugtenburg et al.   HAEMATOLOGICA

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

(2017) Andrew Davies et al.   Lancet Haematology

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone

(2017) Gabriel N. Hortobagyi et al.   JAMA Oncology

XELOXvs.FOLFOX in metastatic colorectal cancer: An updated meta-analysis

(2016) Yu Guo et al.   CANCER INVESTIGATION

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

(2016) Mohamed Touati et al.   SUPPORTIVE CARE IN CANCER

Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study

(2016) Junichi Kurebayashi et al.   Breast Cancer

Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents

(2016) Rahul Mhaskar et al.   JAMA Oncology

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study

(2015) A. Lassalle et al.   ANNALS OF ONCOLOGY

Meta-analysis: rapid infliximab infusions are safe

(2013) H. C. Neef et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

(2013) Xavier Pivot et al.   LANCET ONCOLOGY

Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension

(2012) S. R. Shah et al.   ANNALS OF ONCOLOGY

Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer

(2011) Norikazu Masuda et al.   BREAST CANCER RESEARCH AND TREATMENT

Chemotherapy-Related Hospitalization Among Community Cancer Center Patients

(2011) M. J. Hassett et al.   ONCOLOGIST

Home care—a safe and attractive alternative to inpatient administration of intensive chemotherapies

(2011) François Lüthi et al.   SUPPORTIVE CARE IN CANCER

Review of the Safety and Feasibility of Rapid Infusion of Rituximab

(2010) Jill Atmar   Journal of Oncology Practice

Rapid infusion of rituximab over 60 min

(2009) Mark Tuthill et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A Phase I-II Study to Determine the Maximum Tolerated Infusion Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function

(2008) M. Siano et al.   CLINICAL CANCER RESEARCH

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

(2008) Jim Cassidy et al.   JOURNAL OF CLINICAL ONCOLOGY

Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

(2008) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE